This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Dynatronics Corporation (DYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Dynatronics Corporation (DYNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Dynatronics Corporation (DYNT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -85.29% and 5.02%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Dynatronics Corporation (DYNT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -125% and 11.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of -11.43% and 9.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 11.11% and 4.84%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) delivered earnings and revenue surprises of 6.06% and 10.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Dynatronics Corporation (DYNT) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -80% and 0.47%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - DYNT, INGN, AVNS - which are expected to provide long-term gains.
3 Medical Instruments Stocks to Buy as Inflation Clouds Prospects
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on rising demand for digital health. SWAV, MLAB and DYNT are set to gain the most. Yet, the ongoing inflation in the form of rising freight, raw material and labor costs is an overhang.
Dynatronics Corporation (DYNT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of 33.33% and 2.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of 107.19% and 10.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Dynatronics Corporation (DYNT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of -11.11% and 0.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Dynatronics Corporation (DYNT) Reports Break-Even Earnings for Q3
by Zacks Equity Research
Dynatronics Corporation (DYNT) delivered earnings and revenue surprises of 100.00% and 0.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Dynatronics Corporation (DYNT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Dynatronics Corporation (DYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Have Faith in Rising P/E: Play 5 Top-Ranked Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Orthofix (OFIX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Orthofix (OFIX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.